Cannabis Sector Down 29% in 2018 – Is it Time to Buy?

Warren Buffett famously stated that as an investor it is smart to be “fearful when others are greedy and greedy when others are fearful.”

If the most successful investor ever is correct, now is the time to be greedy with cannabis stocks.

The North American cannabis stock index has fallen into a bear market – down 29% on the year. Continue reading “Cannabis Sector Down 29% in 2018 – Is it Time to Buy?”

Two Early Leaders to Profit from New York’s $3.1 Billion Cannabis Market

A new report predicts that New York is set to grow into the second largest cannabis market in the United States behind California.

Today I am going to share what is happening in New York and reveal two of the best cannabis stocks to potentially profit.

The New York City Comptroller predicts that New York’s recreational cannabis market could generate $3.1 billion in annual sales and $1.3 billion in new state and local taxes.
Continue reading “Two Early Leaders to Profit from New York’s $3.1 Billion Cannabis Market”

Cannabis Game Changer to Repeat Netflix’s 5,000% Gain?

Game-changing companies don’t come along very often. But when they do, shareholders usually see big gains.

This pattern continues to repeat itself in the stock market.

Netflix (NFLX) is a recent example.

Back in 2007, Netflix introduced a game changer in the home entertainment industry, releasing a new service that enabled customers to stream movies from the internet into their homes. Continue reading “Cannabis Game Changer to Repeat Netflix’s 5,000% Gain?”

Another 63% Gain in 3 Days?

The Cannabis IPO market just produced another big winner. If my analysis is correct, the next great opportunity is right around the corner.

Tilray (TLRY) is an early leader in the global cannabis industry with a market cap of $2 billion. Tilray just became the first ever Canadian cannabis company to list shares directly on the US-based NASDAQ. Continue reading “Another 63% Gain in 3 Days?”

Cannabis IPO Alert: Tilray Starts Trading in $144 Million IPO

Cannabis IPOs have a proven history of delivering big gains in a short amount of time.

That was most recently on display with The Green Organic Dutchman (TGOD).

This young and promising Canadian cannabis company began trading on the Toronto Stock Exchange on May 7.

Within four weeks shares were up more than 100%. Despite a pullback, shares are still up 50% from the IPO price. Continue reading “Cannabis IPO Alert: Tilray Starts Trading in $144 Million IPO”

Promising Cannabis Biotech Jumps 23% on Great FDA News

June 26 was a groundbreaking day for the US cannabis industry.

That’s the day the FDA, the US agency responsible for approving new drug candidates, approved its first-ever cannabis drug.

The first-ever medical treatment derived from a marijuana plant will hit the U.S. market in a few months after regulators on Monday gave the epilepsy treatment the green light. Continue reading “Promising Cannabis Biotech Jumps 23% on Great FDA News”

2 Early Canadian Leaders Ready to Soar on Buyout Rumors

October 30, 2017 was one of the best days of the year for the young cannabis industry.

That’s the date when Constellation Brands (NYSE: STZ), the second-largest US beer maker, announced a 10% stake in Canopy Growth (NYSE: CGC), the largest Canadian cannabis company.

It was a groundbreaking moment for the cannabis industry because it was the first time that a big alcohol company had invested directly in a cannabis company. Continue reading “2 Early Canadian Leaders Ready to Soar on Buyout Rumors”

New Entry into Germany’s Cannabis Industry up 475% in 12 Months

Germany has quickly emerged as one of the fastest-growing medical cannabis markets in the world.

According to a study on the German health insurance market, 500 German patients requested medical cannabis in January of 2017.

In December of the same year, the number of patients requesting reimbursements for cannabis prescriptions skyrocketed to 13,000.

What was the biggest factor that drove the huge spike? Continue reading “New Entry into Germany’s Cannabis Industry up 475% in 12 Months”

Leading Cannabis Biotech Could Soar on June 27

Blockbuster drugs are the holy grail of the pharmaceutical industry.

When annual sales of a hot new drug break the $1 billion mark, investors are usually rewarded with big gains.

This is what began happening in 2012 with Gilead Science (Nasdaq: GILD).

In 2013, the FDA approved Gilead’s hepatitis C drug Sovaldi. Continue reading “Leading Cannabis Biotech Could Soar on June 27”